207
Participants
Start Date
July 27, 2023
Primary Completion Date
March 13, 2025
Study Completion Date
March 13, 2025
JZP258 (XYWAV)
"Narcolepsy Cohort: Initiate dosage per XYWAV label and titrate to effect.~IH Cohort: Initiate dosage per XYWAV label and titrate to effect.~Narcolepsy \>9-Gram Cohort: XYWAV titrated to a dosage of \>9 to 12 grams."
Geisinger Clinic, Scranton
Abington Neurological Associates, LTD, Abington
Clinical Research of Gastonia, Gastonia
Stern Research Partners, LLC, Huntersville
Bogan Sleep Consultants, LLC, Columbia
NeuroTrials Research, Inc., Atlanta
Centricity Research Rincon - DBA IACT Health Southeast Lung Associates Research, Rincon
Florida Hospital for Children, Winter Park
PharmaDev Clinical Research Institute, LLC, Miami
Meris Clinical Research, LLC, Brandon
Sleep Disorders Center of Alabama, Birmingham
Ohio Sleep Medicine and Neuroscience Institute, Dublin
Cleveland Clinic Main Campus - Clinical Research Unit, Cleveland
CTI Clinical Research Center, Cincinnati
Intrepid Research, Cincinnati
Clinical Neurophysiology Services, P.C., Sterling Heights
St. Lukes Hospital Medical Center, Chesterfield
Comprehensive Sleep Medicine Associates, Houston
Tricoastal Narcolepsy and Sleep Disorders Center, Sugar Land
Sleep Therapy & Research Center, San Antonio
FutureSearch Trials of Neurology, Austin
Perseverance Research Center, LLC, Scottsdale
Santa Monica Clinical Trials, Los Angeles
Long Beach Research Institute, Lakewood
Amnova Clinical Research, Irvine
SDS Clinical Trials, Inc., Santa Ana
Stanford School of Medicine, Redwood City
TriValley Sleep Center, San Ramon
Neurocare, Inc., dba Neurocare Center for Research, Newtown
Heritage Medical Research Clinic, University of Calgary, Calgary
AMNDX Inc, Markham
Johda Tishon Inc, Toronto
Lead Sponsor
Jazz Pharmaceuticals
INDUSTRY